Hydrochloric Acid

Hydrochloric Acid

SCHEMBL356747

CCCCCCCCCCCCCCCCCC(C)(C)NCc1ccccc1.Cl

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SIGMAR1 known ✓ Q99720 1/20 0.41
MAOA known ✓ P21397 1/20 0.39
EPHX2 P34913 4/20 0.46
L3MBTL1 Q9Y468 1/20 0.42
KDM4E B2RXH2 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
FAAH O00519 2/20 0.40
DNM1 Q05193 2/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
TP53 P04637 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PKM P14618 1/20 0.39
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
ATM Q13315 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3299241 1.00 EPHX2 (0.46) EPHX2L3MBTL1KDM4ECYP3A4MAPT
Hydrochloric Acid SCHEMBL11150761 1.00 EPHX2 (0.46) EPHX2L3MBTL1KDM4ECYP3A4MAPT
Hydrochloric Acid SCHEMBL8417309 1.00 EPHX2 (0.46) EPHX2L3MBTL1KDM4ECYP3A4MAPT
Hydrochloric Acid SCHEMBL9725437 1.00 EPHX2 (0.46) EPHX2L3MBTL1KDM4ECYP3A4MAPT
Hydrochloric Acid SCHEMBL28716627 1.00 EPHX2 (0.46) EPHX2L3MBTL1KDM4ECYP3A4MAPT
Hydrochloric Acid SCHEMBL2232233 1.00 EPHX2 (0.46) EPHX2L3MBTL1KDM4ECYP3A4MAPT
Hydrochloric Acid SCHEMBL8988138 0.98 EPHX2 (0.45) EPHX2L3MBTL1KDM4ECYP3A4MAPT
SCHEMBL5606363 0.98 EPHX2 (0.47) EPHX2L3MBTL1SIGMAR1FAAHDNM1
SCHEMBL2369686 0.98 EPHX2 (0.47) EPHX2L3MBTL1SIGMAR1FAAHDNM1
SCHEMBL2370129 0.98 EPHX2 (0.47) EPHX2L3MBTL1SIGMAR1FAAHDNM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 574 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743050-A1 3-HYDROXYPROPYLESTERS AS FOAM AND VISCOSITY MODULATING AGENTS IN SURFACTANT CONTAINING FORMULATIONS Symrise AG (DE) 2026-05-20 EP claimed
WO-2025011747-A1 3-HYDROXYPROPYLESTERS AS FOAM AND VISCOSITY MODULATING AGENTS IN SURFACTANT CONTAINING FORMULATIONS SYMRISE AG (DE) 2025-01-16 WO claimed
US-20230329994-A1 Surfactant Containing Formulation of Pseudo-Ceramides SYMRISE AG (DE) 2023-10-19 US claimed
CN-115980332-A Enhancing liquid capable of improving sensitivity of immunodiagnostic reagent and preparation method thereof 广州科方生物技术股份有限公司 2023-04-18 CN claimed
EP-3986365-A1 SURFACTANT CONTAINING FORMULATION OF PSEUDO-CERAMIDES Symrise AG (DE) 2022-04-27 EP claimed
WO-2022053140-A1 SURFACTANT CONTAINING FORMULATION OF PSEUDO-CERAMIDES SYMRISE AG (DE) 2022-03-17 WO claimed
CN-112094445-A Wear-resistant rubber for slurry pump and preparation method thereof 三联泵业股份有限公司 2020-12-18 CN claimed
US-20170251666-A1 ONE-PART SOLID GLUTARALDEHYDE-QUATERNARY AMMONIUM INCLUSION OR OCCLUSION COMPLEXES AND THEIR USES ECOLAB USA INC. 2017-09-07 US claimed
US-20120263657-A1 Promoting Whole Body Health THE PROCTER & GAMBLE COMPANY 2012-10-18 US claimed
EP-1885326-A2 REGULATION OF MAMMALIAN KERATINOUS TISSUE USING PERSONAL CARE COMPOSITIONS COMPRISING CETYL PYRIDINIUM CHLORIDE The Procter and Gamble Company (US) 2008-02-13 EP claimed
US-20070020221-A1 Regulation of mammalian keratinous tissue using personal care compositions comprising cetyl pyridinium chloride PROCTER & GAMBLE COMPANY, THE 2007-01-25 US claimed
WO-2006124990-A2 REGULATION OF MAMMALIAN KERATINOUS TISSUE USING PERSONAL CARE COMPOSITIONS COMPRISING CETYL PYRIDINIUM CHLORIDE THE PROCTER & GAMBLE COMPANY (US) 2006-11-23 WO claimed
EP-4743050-A1 3-HYDROXYPROPYLESTERS AS FOAM AND VISCOSITY MODULATING AGENTS IN SURFACTANT CONTAINING FORMULATIONS Symrise AG (DE) 2026-05-20 EP disclosed
US-12564551-B2 Composition or oat extract comprising avenanthramide and β-glucan SYMRISE AG (DE) 2026-03-03 US disclosed
US-20250381253-A1 MUTANASES AND ORAL CARE COMPOSITIONS COMPRISING SAME NOVOZYMES A/S (DK) 2025-12-18 US disclosed
US-12497478-B2 High molecular weight block copolymers comprising repeating units derived from monomers comprising lactam and acryloyl moieties and hydrophilic monomers, compositions, and applications thereof ISP INVESTMENTS LLC (US) 2025-12-16 US disclosed
US-3982892-A A HALO-TRIAZINE AND DIALKANOYL DIALKYL GLYOXIME OR TETRAALKANOYL GLYCOLURIL COLGATE-PALMOLIVE COMPANY (US) 1976-09-28 US disclosed
US-3971725-A 2-Mercaptoquinoxaline-1-oxides, salts thereof and 2-(1-oxoquinoxalinyl)disulfides in detergent compositions COLGATE-PALMOLIVE COMPANY (US) 1976-07-27 US disclosed
US-3966928-A HAIR AND SKIN CONDITIONERS COLGATE-PALMOLIVE COMPANY (US) 1976-06-29 US disclosed
US-3941731-A Powder paints containing aluminum and nickel II FORD MOTOR COMPANY (US) 1976-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070020221-A1 Regulation of mammalian keratinous tissue using personal care compositions comprising cetyl pyridinium chloride RBP1, PROC, RBP4 SIGMAR1 4608/4885MAOA 4173/4885EPHX2 4127/4885
US-12497478-B2 High molecular weight block copolymers comprising repeating units derived from monomers comprising lactam and acryloyl moieties and hydrophilic monomers, compositions, and applications thereof MRPL9, PRMT9, MRPL19 SIGMAR1 1442/4885MAOA 3605/4885EPHX2 3082/4885
US-12564551-B2 Composition or oat extract comprising avenanthramide and β-glucan CUTA, HLA-A, OAT SIGMAR1 455/4885MAOA 156/4885EPHX2 4708/4885
US-20170251666-A1 ONE-PART SOLID GLUTARALDEHYDE-QUATERNARY AMMONIUM INCLUSION OR OCCLUSION COMPLEXES AND THEIR USES GLUL, OTUB1, OGDH SIGMAR1 2862/4885MAOA 2687/4885EPHX2 4280/4885
US-20230329994-A1 Surfactant Containing Formulation of Pseudo-Ceramides SGMS1, SGMS2, CERT1 SIGMAR1 1853/4885MAOA 824/4885EPHX2 609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.